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Iron Addiction In Tumor Initiating Cells: A Novel Therapeutic` Target In Ovarian 
Cancer 
Debargha Basuli, M.D., PhD 
University of Connecticut, 2016 
Ovarian cancer is a highly lethal malignancy that has not seen a major therapeutic 
advance in over 30 years. We demonstrate that ovarian cancer exhibits a targetable 
alteration in iron metabolism.  Ferroportin (FPN), an iron efflux pump, is decreased and 
transferrin receptor (TFRC), an iron importer, is increased in ovarian cancer 
tissue.  Expression of FPN and TFRC are strongly associated with patient 
survival.  Ovarian cancer tumor-initiating cells demonstrate a similar profile of iron 
excess.  Iron deprivation induced by desferroxamine, knockout of IRP2, or 
overexpression of FPN preferentially blocks growth of tumor initiating cells.  Iron 
restriction inhibits invasion, synthesis of MMPs and IL6, and reduces intraperitoneal 
spread of tumor cells in vivo.  Growth of ovarian tumors is inhibited by induction of 
ferroptosis, an iron-dependent form of cell death.  Thus, enhanced levels of iron create a 
metabolic vulnerability that can be exploited therapeutically. We show that this 
dependence is already evident in the tumor initiating cell and creates a new therapeutic 
opportunity.  Thus, alterations in iron import and export in ovarian cancer result in an iron 
acquisitive phenotype and an increase in metabolically available iron.  A reduction in 
intracellular iron decreases IL6, which reduces MMPs, invasion and intraperitoneal 
metastases.  Iron dependence can be targeted in two ways:  by reducing intracellular iron 
with chelators, or by treating with agents that induce iron-dependent cell death. 
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INTRODUCTION 
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Introduction of thesis 
This thesis details my research on iron addiction exhibited by ovarian cancer tumor 
initiating cells (TICs) (or popularly known Cancer Stem Cells/CSCs) and targeting it to 
modulate tumor growth. In this introduction, first I will provide a brief overview of the 
relation between iron and cancer. Next, I will provide a background for ovarian cancer. I 
will then describe the current concept about tumor initiating cells. Finally I will introduce 
our concept of how the iron phenotype in the ovarian TICs can be targeted. Altogether, 
this introduction will underscore the rationale for pursing the studies described in this 
thesis.  
Overview of role of iron in human body 
Iron is an essential element for mammalian cells. Iron is critical for cell division, growth 
and metabolism. It is contained or acts as a cofactor in many vital enzymes. In mammalian 
cells, iron enables ribonucleotide reductase activity thereby helping in DNA replication 
and cell growth(1) . Reversible coordination of O2 and its transport by iron containing 
metalloproteins (hemoglobin and myoglobin) is crucial for life. Iron-sulphur proteins are 
best known for their role in oxidation-reduction reactions of the mitochondrial electron 
transport system. Cytochromes contain a variety of heme cofactors and are involved in 
electron transfer reactions required for cellular respiration(2). Iron has important role in 
cellular detoxification through enzymes like peroxidase and catalase (3). Thus iron is 
beneficial to the basic biological processes to sustain life. 
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Normal iron homeostasis in human 
The main source of iron in human is through diet. The majority of dietary iron is absorbed 
by the enterocytes in the duodenum.  A ferric reductase enzyme, duodenal cytochrome 
B (DcytB) present of the luminal border of the enterocytes reduces any ferric iron ( Fe3+ ) 
to ferrous iron ( Fe2+). Divalent metal transporter 1 (DMT1), another protein in the 
enterocytes help in internalizing Fe2+ into the cells and transporting across the cell. On 
the basolateral side of the enterocyte, Fe2+ is again oxidized back to Fe3+ by hephaestin. 
Fe3 + is released by the cell into the circulation through the only known iron exporter in 
mammals called ferroportin (FPN). The body regulates iron absorption mainly by 
regulating the levels of FPN, via hepcidin, an enzyme produced in liver and binds to FPN 
to degrade it. Fe3+ thus released into the blood binds to Transferrin (TF) and circulates 
throughout the body and is delivered to peripheral tissues. Iron bound TF is recognized 
by transferrin receptor (TFR), a cell surface receptor. The Fe3+- TF- TFR complex is 
endocytosed into the cell. In the acidic environment of the endosome, and through the 
enzymatic activity of STEAP reductase, Fe3+ is reduced to Fe2+. TFR is recycled back to 
the cell membrane. With the help of DMT1, Fe2+ effluxes from endosome into the cytosol 
into a pool of loosely bound metabolically active iron, termed as labile iron pool (LIP). Iron 
from this LIP is used for biosynthesis of heme and iron- sulphur clusters, other enzymes 
and the excess iron is stored in an iron storage protein called ferritin. Iron can also be 
pumped out of the cell through FPN.  
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Figure 1. Normal cellular iron homeostasis. 
Upper diagram shows absorption of dietary iron through duodenal enterocyte. 
Lower diagram shows normal cellular iron metabolism. 
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Iron regulatory proteins (IRP1 and IRP2) are the master regulators of iron homeostasis 
and regulate other iron proteins post-transcriptionally (Figure 2). When the cell is iron 
depleted, IRBs bind to the iron response elements (IREs) in the 5’ untranslated region of 
ferritin and FPN mRNAs leading to stalling of translation of these mRNAs. The TFR 
mRNA also has IRE in the 3’ untranslated region. Binding of IRBs to the IRE of TFR 
mRNA stabilizes the mRNA and increased translation of TFR. When the cell is iron 
sufficient, IRBs unbind from the IREs of the respective mRNAs leading to increased 
translation of ferritin and FPN, and decrease in TFR translation. 
 
 
 
 
 
 
 
 
 
Figure 2. Control of iron metabolism through IRB.  
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Iron and cancer 
Despite its beneficial role of iron, iron is found to the culprit of diverse pathological 
conditions in human including cancer. There is a growing body of evidence, both 
epidemiological and biological about the strong association of iron and cancer.  
In one of the early observational studies, Stevens et al demonstrated that in a cohort of 
14000 human participants, higher TF saturation was associated with increase in risk of 
cancer in men within a follow up period of 10-13 years(4). Several studies were conducted 
later, most of which indicated a general trend of increased cancer risk with increased body 
iron stores. Other studies have shown that in hemochromatosis, a genetic disease 
(mutation in HFE gene) leading to massive iron accumulation with in the body, the risk of 
cancer is about 20-200 fold higher than normal people (5, 6). Hemochromatosis patients 
are at increased risk of mainly liver cancer, including cancers in other organs like 
pancreas, breasts and colon (7, 8). In an interventional study, it was observed that 
reduction in body iron through repeated phlebotomy in elderly men was associated with 
overall reduction in cancer risk (9).   
The underlying mechanisms of the strong association of iron and cancer are not 
understood clearly. One popular hypothesis is iron may promote tumor initiation through 
its ability of production of reactive oxygen species via Fenton reaction. Iron reacts with 
hydrogen peroxide to form hydroxyl and hydroperoxyl radicals as follows: 
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Fe2+ + H2O2 → Fe3+ +  HO•    + OH− 
Fe3+ + H2O2 → Fe2+ +  HOO•    + H+ 
ROS produced in Fenton reaction can mutate DNA through oxidative dmage potentially 
leading to tumor initiation(10, 11).  
During the last two decades, several studies manifested that iron metabolism is altered 
in cancer and many iron proteins are found to have important contribution in tumor growth. 
TFR, the major iron import protein has been shown to be highly expressed in many 
cancers including breast cancer, lung cancer, bladder cancer, glioma to name a few(3). 
Studies have shown that targeting TFR can be effective as a therapeutic strategy to halt 
cancer cell growth in vitro and in vivo(12). Antibodies against TFR have shown promising 
results in preclinical trails (13). Cytotoxic moieties conjugated to its ligand TF has been 
used to target highly expressed TFR within the cancer selectively (14).  Ferritin, the iron 
storing protein is found to contribute to tumor growth. In B cell lymphoma and other HRAS 
expressing cancers, ferritin is found to be downregulated, thereby releasing the stored 
iron into the metabolically active labile iron pool of the cancer cells to promote tumor 
growth(15-17). Ferritin is transcriptionally upregulated by TNF(18). TNF induced ferritin 
upregulation is mediated by NF-κB in the fibroblasts (19). In their review, Torti et al (3), 
opine that increased ferritin through NF-κB in the fibroblast might help in sequestering 
iron and thereby preventing oxidative stress within the tumor microenvironment leading 
to tumor survival. Ferritin may also promote angiogenesis in cancer by binding to high 
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molecular weight kininogen (HMWK)(20). Thus ferritin can modulate tumor growth both 
through up and down regulation.  
The FPN- hepcidin regulatory axis is the major pathway through which systemic iron 
levels are regulated with in the body (21). When iron level is high within the body, hepcidin 
is induced in the liver. Hepcidin binds to the FPN in the enterocytes and downregulates 
FPN leading to lesser iron absorption (22). FPN and hepcidin are expressed in breast 
epithelial cells (23). FPN is found to be downregulated in breast cancer cells at protein 
level, probably through a local autocrine FPN-hepcidin loop in the cancer cells (23). FPN 
mRNA expression pattern in the tumor tissue of breast cancer patients is significantly 
associated with patient survival and thus can predict clinical outcome of the disease (23).  
IRP2 is overexpressed in breast cancer and plays an important role in iron accumulation 
in breast cancer (24). IRP2 is shown to upregulate tumor growth and may contribute to 
the poor outcome of the breast cancer patients (24).  
Thus there is substantial evidence, both factual and conceptual that iron plays a pivotal 
role in cancer initial and progression. Altered iron metabolism has been suggested as a 
“hallmark of cancer”(25). A subset of iron genes comprising of 16 genes (termed as iron 
regulatory gene signature, IRGS) has been shown to be superior for risk stratification in 
breast cancer compared to conventional prognostic factors (26). Iron genes and proteins 
are being evaluated for prognosis and therapy in several types of cancers (23, 27, 28). 
Although a lot of studies have been conducted to understand the relation between iron 
and different cancer types, a little work has been done in respect to ovarian cancer, the 
5th most common cancer in women in US and the most lethal gynecological malignancy. 
 
 
9 
 
In this thesis, the objective of my research work is to explore the characteristics of iron 
metabolism in ovarian cancer, particularly high grade serous ovarian cancer (HGSOC). 
 
High grade serous ovarian cancer (HGSOC) 
Overview of ovarian cancer 
Ovarian cancer is the fifth leading cause of cancer-related deaths among women in the 
United States(29).  In 2014, approximately 22,000 women were diagnosed with ovarian 
cancer, and approximately 14,000 died of the disease, making it the most lethal of the 
gynecologic malignancies (29, 30). Ovarian cancer is a heterogeneous disease 
composed of multiple subtypes that are defined both histologically (31) and molecularly 
(32-34).  High grade serous ovarian carcinoma is the most common histologic subtype, 
accounting for over 50% of ovarian epithelial malignancies.   The 5 year survival rate of 
patients with HGSOC is a dismal 9-34% (31).   
Origin of HSOC 
To more effectively approach HGSOC, efforts have focused on identifying its cell of origin.  
This subject remains an area of active debate (35). Since early 70s, ovarian surface 
epithelium (OSE) was proposed to be the origin of HGSOC by Fathala (36). For 30 years, 
the exact process of how OSE transforms into HGSOC was never precisely understood. 
In the 90s, following the discovery of BRCA1 and BRCA1 genes to be responsible for 
high risks of breast and ovarian cancer (37), a new hypothesis about the cell of origin of 
HGSOC started to emerge. After this, salpingo-oophorectomy became the standard 
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practice for prevention of ovarian cancer in women who were carriers of germline 
mutations in BRCA1 and 2. With the availability of surgical samples from preventive 
salpingo-oophorectomy, the pathologists started to carefully examine the specimen and 
surprising they didn’t find any lesion in the ovaries. Instead, a dysplastic lesion was found 
in the fimbriated end of the fallopian tube samples. Following this observation, a standard 
protocol for systematic evaluation of the surgical samples of the fallopian tubes was 
adopted, called SEE-FIM (referenced in (38)) which led to the identification of an occult 
noninvasive and invasive carcinomas in the fallopian tubes(38, 39). Subsequently, Peik 
et al proposed the occult tubal carcinoma might be the precursor lesion for the high grade 
serous carcinoma in the ovary (40). Several other findings upheld histological, molecular 
and genetic evidence that pointed towards the fallopian origin of HGSOC. Genetic 
expression studies demonstrated that the expression profile of HGSOC resembled 
fallopian tubular epithelium more closely compared to the OSE (41). Tubal intraepithelial 
carcinoma was found positive in 48% of the women with HGSOC but who were not 
carriers of BRCA mutations (42). This lesion was only found in patients with serous 
carcinoma but not in other types of ovarian cancer; hence the term “serous tubular 
intraepithelial carcinoma (STIC) “was proposed for this lesion (42). The first defining 
feature of STIC was the “p53 signature”, characterized by evidence of DNA damage, 
TP53 mutations and P53 protein stabilization found within the secretory cells of the 
fallopian epithelia. (41). Pathological studies of surgical specimens of STICs and HGSOC 
showed that 92% of the STIC have TP53 mutation and are identical to the TP53 mutation 
in the concurrent pelvic high grade cancer supporting the evidence of clonal relationship 
between the two lesions(43).  
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Pathogenies of HGSOC 
The process of transformation of STIC into HGSOC is poorly characterized. Traditionally 
ovarian serous carcinomas have been graded into low grade and high grade. Recent 
molecular and genetic studies have shown that the low and high grade serous ovarian 
cancer have entirely distinct pathogenies pathways (44). Based on the histological 
features and clinical outcome, epithelial ovarian cancer is grouped into 2 major types: 
type 1 and type 2 (45). Type 1 includes low grade serous cancer, low grade endometriod 
cancer, mucinous cancer and some clear cell cancers that arise from a defined precursor 
called borderline tumors (46).Type 1 cancer evolves in a stepwise fashion and exhibit 
more chromosomal stability. Common mutations in Type 1 cancer are Type 1are in 
KRAS, BRAF, PTEN, CTNNB1 and TGFBR2 (46). Type 2 cancer mostly includes the 
HGSOC. HGSOC progresses rapidly and contain TP53 mutations. TP53 mutation in the 
fallopian tube fimbria is probably the earliest event in HGSOC pathogenesis since STICs 
have shortened telomeres compared to HGSOC (47). A TCGA pilot study of HGSOC, 
showed nearly 100% of the tumors harbor TP53 mutation and catalogued low prevalent 
but statistically significant recurrent somatic mutations in 9 other genes including NF1, B1 
and CDK12 RCA1/2, RB1 and CDK12 (48).  c-myc amplification is a common finding in 
advanced-stage ovarian cancer (49). TCGA also identified widespread DNA copy number 
variation in the tumors. Based on these findings, a viable model of progression of HGSOC 
has been proposed where the primary events include p53 loss and BRCA mutation 
leading to a deficiency of homologs recombination repair (HRR) that initiate chromosomal 
instability and widespread copy number (CN) change (Figure 3) (46) (50). Thus though 
 
 
12 
 
early events in HGSOC are more or less properly defined, HGSOC is characterized by a 
high level of genomic heterogeneity(51) making it difficult  to generalize its genetics.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Proposed model for initiation and progression of HGSOC. 
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Tumor initiating cells (TICs) 
Overview of the concept of TIC 
One current popular concept of tumorigenesis is that the tumors are composed of 
heterogeneous cells populations with different biological properties and tumorigenic 
potentials. A small subset of the tumor cells, called the tumor initiating cells (TICs) is 
thought to play a crucial role in tumor development, chemoresistance and relapse (52, 
53). The recent “cancer cell hypothesis” upholds the concept that tumor growth is not a 
simple monoclonal expansion of the transformed cells but a decisively driven by minority 
of these cellular populations (TICs) that display stem like properties (54).  The concept of 
TICs is evolving and there remain several controversies concerning this model.  The TICs 
are defined possess inherent ability for unlimited self-renewal through asymmetric 
division and differentiation leading to the formation of a tumor mass (55). “Asymmetric 
division” is defined as the process where a mother cell divides into two daughter cells: 
one daughter cell being the exact clone of the parental cell while the second daughter cell 
may not necessarily have the parental traits (56). Thus, tumors arising from TIC consist 
of TICs and mixed population of cells which gives rise to the full heterogeneity of the 
tumor (57). The working model of TICs defines the properties of such cells as having the 
following properties (58): 
1) Unlimited proliferative ability 
2) Potential to self-renew indefinitely in an undifferentiated form 
3) Resistant to chemo and radio therapy 
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4) High DNA repair capacity 
5) Ability to propagate a tumor by expansion of cells that are deregulated at various 
stages of differentiation 
The TICs are reported to be characterized by specific identifying surface markers. 
Although a distinctive profile of surface markers have been identified and described, the 
profile of such surface markers have been found to differ from tumor to tumor and 
probably from patient to patient (54).  
TICs in ovarian cancer 
The theory origin of a TIC is equivocal. Some suggest that TICS not necessarily arise 
from an oncogenic transformation from a normal stem cell but can arise from a progenitor 
or differentiated cell acquiring stem like characteristics through un-differentiation (59). 
However there is also evidence that TICs can arise from neoplastic transformation of a 
normal stem cell (60, 61).  
The first report of stem cells in ovarian cancer was made in 2005 (62). The description of 
the stem cell was derived from a single cell isolated from the ascetic fluid of an ovarian 
cancer patient that could sequentially propagate tumors over several generations. 
Following that, TICs populations have been identified and studied in primary ovarian 
tumors and ovarian cancer cell lines. The major drawback in studies of ovarian TICS is 
the lack of a clearly defined distinct cell surface marker. This makes isolation of a pure 
population of ovarian TICs very difficult. In recent studies, several attempts have been 
made to characterize the ovarian TICs based on the known stem cell markers of other 
types of solid malignancies. CD44, CD24, CD133, CD117, aldehyde hydrogenase 
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isoform 1 (ALDH1A1) have been proposed to denote the stem cell signature within 
ovarian tumors and have been used to isolate these cells from entire bulk of the tumor 
cells (63-66). Ovarian TICs have also been isolated based on their ability to efflux DNA 
dyes (67) and this population of cells are termed as “side population”. The side 
populations exhibit properties of tumorigenicity and chemo resistance at par with the 
properties of a TIC (68) but have shown to have heterogeneity for the known stem cell 
markers. Ovarian TICs isolated based on the surface markers and side population 
correlate with drug resistance and worse clinical prognosis (69). Genetic analysis of these 
cells were enriched in ovarian cancer patients suffering from high recurrence (69). 
Though the cells isolated by the abovementioned ways correlated with some of the 
defining features of stem cell properties, these models have always been debated as a 
true representation of TICs. Some more recent studies have used the functional 
properties of the stemness rather than isolating them based on cell surface markers. Stem 
cells are isolated from colonies growing from single cells possessing self-renewal 
capacity in culture conditions which force the cells to remain in their undifferentiated 
ground state (70).  
Why studying TICs in ovarian cancer so important 
The main challenge for ovarian cancer therapy is to overcome the resistance to treatment 
and recurrence of the disease. Current management strategy of advanced ovarian cancer 
is cytoreduction or tumor debulking surgery followed by chemotherapy to eradicate 
residual cancer (71). The chemotherapy consists of platinum (cisplatin or carboplatin) and 
taxane based agents. Though there is a remission of the cancer in 80% of the patients, 
majority of the patients suffer from a relapse within 2 years. The low 5 year survival rate 
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of only 10-30% is mainly because of the recurrence (72). The standard platinum based 
chemotherapy is very efficient in eradicating the bulk of the tumor mass. But recent 
studies show that the cisplatin fails to remove a core of cancer stem cells (CSCs) or tumor 
initiating cells (TICs) (73) and chronic treatment with this drug promotes enhanced 
damage repair and tumor progression and invasion (74). The TICs are thought to be 
resistant to traditional cytotoxic drugs due to high expression of ATP-binding cassette 
drug transporters and anti-apoptotic proteins, and an efficient DNA damage repair 
mechanism (75). Some current studies have also demonstrated that the residual TICs 
secrete soluble factors that facilitate the recurrence of the tumor (76).  Thus there is 
accumulating evidence that TICs have crucial role if ovarian cancer progression and 
relapse. 
Because of the above mentioned reasons, the current approach of the anti-cancer 
research is slowly shifting from conventional chemotherapies that target the bulk tumor 
cells to molecular targeted therapies against the TICs. This is probably more important in 
the context of ovarian cancer than any other cancer types. As discussed earlier, the lack 
of a thorough characterization of the ovarian TICs complicates any chemotherapy 
research aimed to target the ovarian TICs.   
My thesis is a study to characterize these ovarian TICs in addition of what is currently 
known. We have tried to shed light to iron phenotype of the TICs that may uncover a 
targetable iron dependence of these cells. 
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Thesis Outline 
As discussed in the introduction, iron seems to play an important role in tumorigenesis 
and tumor growth and invasiveness of different kinds of cancers. In most of the cancer, 
the net result of the alteration of the iron proteins is an increase in intra cellular iron levels 
leading to an increased proliferation. Whether this alteration of iron is acquired at an early 
stage of TICs is unknown and has not been explored. A little is known about the role of 
iron in ovarian cancer, particularly HGSOC.   
The objective of this thesis is to provide insight in the iron phenotype of the TICs of 
HGSOC by addressing the following questions: 
1) Is there any distinct iron phenotype in the tumor of the HGSOC patients? 
2) Do iron gene and proteins predict clinical outcome of these patients? 
3) Is iron metabolism altered in the ovarian TICs? 
4) Do the ovarian TICs exhibit any dependence to iron metabolism? 
5) Can iron metabolism be targeted in TICs chemotherapeutically? 
In chapter 2, I will discuss the experimental methods used to address the questions. 
Chapter 3 describes the iron phenotype of the tumors in HGSOC patients. Here I will 
demonstrate that HGSOC express high iron import proteins and low iron export proteins. 
. In chapter 4 I will further show that the mRNA expression of the iron proteins in tumor 
correlates with the clinical outcome of the patients. Chapter 5 describes the profile iron 
genes and proteins in ovarian TICs. We used patient derived ovarian TICs and a genetic 
model for ovarian TICs to characterize the iron parameters in these cells. Chapter 6 
discusses an important finding of enhanced sensitivity of the ovarian TICs to iron 
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alteration. In chapters 7 and 8 I will show two major ways of how iron can be targeted in 
the ovarian TICs to modulate tumor growth and invasion. 
Chapter 9 will provide elaborate discussion of the observations made in the study. 
Chapter 10 will provide a list of references. 
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CHAPTER 2 
METHODS AND MATERIALS 
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Cell isolation from tissues 
Patient derived ovarian TICs were isolated from tumor tissues obtained from HGSOC 
patients who had not received neo-adjuvant therapy and normal fallopian stem cells from 
unaffected fimbrial tissue of the same patient (70) (Yamamoto Y., et al., in preparation). 
The tissues were digested in 2mg/ml collagenase A (Roche) at 37°C for 1.5 hour. 
Disaggregated cells were cultivated onto a feeder layer of lethally irradiated murine 3T3-
J2 cells in stem cell culturing media (SCM-6F8) (70). SCM media contains a cocktail of a 
Notch agonist, a ROCK (Rho Kinase) inhibitor, a Bone Morphogenetic Protein (BMP) 
antagonist, a Wnt agonist, a mitogenic growth factor, insulin or IGF, a TGFP signaling 
pathway inhibitor, and nicotinamide. Single cells were isolated from the cell clones 
growing on the feeder layer and cultured further on a second feeder layer in SCM media. 
Only the cells that are capable of self-renewal (stem cell property) formed clones. Each 
of the clones originating from a single cell represented a clonal expansion of the TIC or 
the normal fallopian stem cell. Clones were then isolated and expanded on a feeder layer 
with SCM media. The patient-derived TIC clones showed a compact cell morphology and 
expressed typical markers of HGSOC, such as Ki67 (proliferative marker), Krt7 and E-
Cadherin (epithelial marker), p53 (indication of stabilized p53 protein due to mutation), 
PAX8 (serous cancer marker)(Yamamoto Y., et al., in preparation).  Consistent with the 
properties of TICs, these cells can self-renew, form tumorspheres and are tumorigenic. 
Xenografts derived from these cells exhibited similar expression profile to the primary 
tumor (Yamamoto Y., et al., in preparation). The normal fallopian stem cells also exhibited 
long term renewability in vitro and the ability to differentiate into secretory and ciliated 
type cells. The cells were PAX8 positive (marker for fallopian tube epithelium stem cells), 
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E-cadherin positive (marker for epithelial origin), and Ki67 positive (marker for 
proliferation). 
 
Immortalization and transformation of fallopian stem cells 
 Adult fallopian stem cells (FTstem) were isolated from fimbrial tissue obtained from 
discarded surgical specimens of women undergoing benign procedures. Cells were 
isolated and cultured in a process similar to that of patient derived TICs mentioned above.  
The FTstem cells thus isolated exhibited long term renewability in vitro and the ability to 
differentiate into secretory and ciliated type cells. The cells were PAX8 positive (marker 
for fallopian tube epithelium stem cells), E-cadherin positive (marker for epithelial origin), 
and Ki67 positive (marker for proliferation). Fallopian stem cells (FTstem) were 
immortalized by infecting with retrovirus expressing hTERT, and SV40 large T antigen as 
previously described(77).  Immortalized cells were further transformed by c-Myc (77).  
Immortalized cells are referred to here as FTi cells and transformed cells as FTt. 
Consistent with the expected properties of tumor-initiating cells, these cells can self-
renew, form tumorspheres and as few as two thousand FTt cells were sufficient to form 
palpable tumors in immunodeficient mice in two weeks, and tumor xenografts 
demonstrated major hallmarks of HGSOC, such as loss of PAX2 and gain of p53, EZH2 
and MUC4 expression, and gene expression profiles similar to HGSOC from human 
patients (77).   
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Infection and isolation of ferroportin-expressing Ftt cells 
 Human FPN cDNA was amplified using Open Biosystem  clone 4823308 (primers shown 
in Suppl. Table 2) and introduced into the lentiviral tetracycline (tet) inducible vector 
pLVX-TetOne-Puro (Takara-Clontech, Mountain View, CA). Lentivirus particles were 
produced by transient cotransfection of the FPN tet-on expression vector and packaging 
vectors (VSVG, pMDLG, and RSV-REV) into 293T cells (78, 79). Viral particles containing 
control empty vector were prepared similarly.  
 
Knock down of IRB2 in Ftt cells 
IRP2 knockdown was performed using lentiviral shRNAs as described (24).   
 
Cell culture 
 Stem cells and tumor progenitor cells (FTstem, CP2-OC, CP2-N, CP34-OC, CP34-N) were 
cultured on δ- irradiated 3T3 fibroblast feeder cells as described. Immortalized and 
transformed stem cells (FTi, FTt) were cultured in DMEM (GIBCO) containing 10% FBS 
(BenchMark). All cells were maintained at 37 °C in a humidified incubator at 7.5% CO2. 
 
Real-time RTPCR 
Briefly, 200 – 400 ng of RNA was reverse transcribed in a total volume of 50 μl with a 
reverse transcription reagents kit (Applied Biosystems). To make a standard curve, serial 
dilutions of RNA from one sample were added to the RT reaction. Aliquots (2 μl) of cDNA 
were added to a 18 μl reaction mixture containing 10 μl of 2× SYBR® Green PCR Master 
Mix (BioRad) and 400 nm primers. Absence of DNA contamination was confirmed by 
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performing PCR from cDNA without reverse transcriptase. Primers used for each gene 
are provided in Supplemental Table 2. 
 
Western blot 
Cells were lysed with NP-40 lysis buffer (25 mM tris (pH 7.4), 1% Triton X-100, 1% SDS, 
1% sodium deoxy-cholate, 150 mM NaCl, aprotinin (2 μg/ml), 1 mM phenylmethylsulfonyl 
fluoride) containing complete protease inhibitor cocktail (Roche Diagnostics). Samples 
were separated by SDS–polyacrylamide gel electrophoresis and transferred to 
nitrocellulose membranes before being incubated with primary and secondary antibodies. 
Bands were detected using chemiluminescence (Thermo Scientific ).  Membranes were 
probed with antibodies to β-actin (Sigma), ferroportin (Novus Biologicals), transferrin 
receptor1 (Invitrogen), IRP2 (Santa Cruz), ferritin H (24), p-STAT3 (cell Signaling) and 
STAT3 (cell Signaling). Western blots were quantified using ImageJ software.  
 
IL6 ELISA 
Cells were seeded in a six well plated in growth media for 24 hours. Conditioned media 
was collected and viable cells counted. IL6 secretion was measured using a Quantikine 
IL6 ELISA kit from R & D systems. ELISA results were normalized to number of viable 
cells at the time of collection of media. 
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Cell Invasion assay 
Cell invasion was conducted by Cultrex® BME Cell Invasion Assay kit by Trevigen in a 
96 well plate with or without basement membrane extract (BME) coating on the inserts as 
per manufacturer’s instructions.  Because FPN affects cell proliferation, we corrected for 
cell number by comparing the number of cells that invaded through basement membrane 
protein to those that migrated through an uncoated 8 micron porous membrane. 
 
Labile iron pool (LIP Assay) 
 Calcein acetoxymethyl ester (CA-AM) was obtained from Molecular Probes. The iron 
chelator, isonicotinoyl salicylaldehyde hydrazone (SIH) (a gift from Dr. P. Ponka, Lady 
Davis Institute for Medical Research, Montreal, Canada) was prepared as a 50 mM stock 
solution in dimethyl sulfoxide (DMSO). Briefly, 25,000 – 50,000 cells were cultured in 96-
well plates (Black with Clear Bottom purchased from Coring) overnight. Cells were loaded 
with 2 μM CA-AM for 15 to 30 minutes at 37°C, and then washed with PBS. 100 μM 
starch-conjugated desferrioxamine (DFO; a generous gift of Biomedical Frontiers, Inc., 
Minneapolis, MN) was added to cells to remove extracellular iron. Fluorescence was 
measured at 485 nm excitation and 535 nm emission with a fluorescence plate reader 
(BioTek Synergy 2). After the fluorescence signal was stabilized, SIH was added at a final 
concentration of 10 μM to remove iron from calcein, causing dequenching. The change 
in fluorescence following the addition of SIH (ΔF) was used as an indirect measure of the 
labile iron pool. 
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Cell viability 
3 × 103 cells were seeded in 96 well plates and treated with either deferoxamine mesylate 
(Sigma), erastin (Selleckchem), or ferrostatin-1 (Selleckchem). Cell viability was 
assessed at 24-72 hours post-treatment using Cell Titer 96 Aqueous (Promega, Madison, 
WI, USA). 
 
Immunohistochemistry 
 Paraffin-embedded formalin-fixed (PEFF) slides of de-identified human tissues obtained 
from HGSOC (10 subjects), low grade serous ovarian cancer (10 subjects), STIC (6 
subjects), normal oviduct (10 subjects), and normal ovary (10 subjects) were collected 
from the biorepository of UCHC (IRB IE-08-310-1). Tissues were immunostained with 
antibodies to human Transferrin Receptor1 (Invitrogen), Ferroportin (Amgen), IRP2 
(LSBio), ferritin H (24), and Ferritin L (Abcam), Cytokeratin 7 (abcam) and Pax 8 
(proteintech). Relevant IgGs were used as negative controls. Images were acquired using 
a Zeiss Axio Scan Z1.  Images of three to four random fields per slide were taken with 
40X objectives using Zeiss Axio Imager A.2 and quantified using the DAB application in 
the open source Fiji software (ImageJ) was used.  Reciprocal intensity was measured by 
subtracting the mean intensity of the stained area of interest from the maximum intensity 
(80). 
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Immunofluorescent staining of cells 
  Cells were plated in 8-chamber slides (BD Falcon) and incubated with anti-human 
Ferroportin 38C8 (Amgen), anti-human Ferritin H (24), anti-Human Ferritin L (Abcam), 
anti-human IRP2 (LSBio), or anti-human Transferrin Receptor (Invitrogen). Rodamine-
Red (Jackson ImmunoResearch), Alexa fluor 488, and Alexa Fluor 555-conjugated 
secondary antibodies were used. Slides were mounted with ProLong Gold anti-fade 
reagent (Invitrogen). Images were acquired using inverted microscopy (Zeiss Axio 
Vert.A1). 
 
Animal Ethics Statement 
 All animal studies were conducted in accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the Association for the Assessment and 
Accreditation of Laboratory Animal Care International (AAALAC). The experiment 
protocol was approved by the Institutional Animal Care and Use Committee (IACUC) at 
the University of Connecticut Health Center (protocol # 100881). 
 
Animal Experiments 
 Female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (NSG; ~ 6 weeks of age) were obtained 
from Jackson Laboratory. 105 FTt cells containing either the FPN tet-on vector or empty 
vector were injected intraperitoneally (i.p) (n=10/group).   FPN was induced in xenografts 
by adding 2 mg/ml doxycycline to the drinking water and mice were euthanized after 4 
weeks.  For erastin treatment, mice were treated with 20 mg/kg Erastin in 2% DMSO/PBS 
or vehicle alone beginning one day after tumor cell injection.  Treatment was continued 
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at five doses per week for 18 days before mice were sacrificed. Tumors were counted 
and the weight of all tumors found within the abdomen of each mouse was measured.  
 
Statistical analysis of cell culture experiments 
Statistical analyses were performed using Excel or Prism 6 (Graphpad software).  All 
experiments were performed at least three times using a minimum of three 
replicates/condition in each experiment. Comparison tests were performed between two 
groups and statistical significance assessed using two-tailed unpaired Student’s t tests. 
Statistics are reported as the mean ± standard deviation.  
 
Publicly available datasets 
For gene expression studies involving publicly available data, three datasets were 
employed: GSE9891 (n = 285) (34); GSE27651 (n=42) (81); and GSE69428 (n=10 paired 
samples). All expression datasets were obtained using an Affymetrix U133 Plus 2 
microarray platform, and datasets were downloaded from the NCBI Gene Expression 
Omnibus (GEO) database (82) as raw CEL files. Data were processed using robust 
microarray average methods as implemented in the Bioconductor software package affy 
(83, 84). Clinical metadata associated with GSE9891 were obtained from the original 
study (34).   
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Statistical analyses of publicly available datasets 
All hypothesis tests comparing mean expression levels for genes of interest between 
groups were run as two-sided t-tests (or paired t-tests for the paired samples) with 
significance level = 0.05.  All data presented are from probesets 223044_at (FPN) and 
237214_s_at (TFRC).  Association between FPN and TFRC gene expression and patient 
survival using progression free and overall survival outcomes reported in the GSE9891 
data was assessed using Cox proportional hazards regression implemented in the 
survival package in R (85, 86).  Significance for regression coefficients was taken at the 
0.05 level.  To examine differences in survival for FPN using Kaplan Meier methods for 
high and low gene expression groups, expression groups were binned by locating an 
optimal risk stratification cutoff point based on unadjusted p values from log-rank tests.  
Testing for differences in gene expression amongst molecular subtypes defined for the 
GSE9891 dataset was done using overall F-tests for across-group comparisons, followed 
by multiple testing adjusted pairwise t-tests for the subgroups. All pairwise tests were two-
tailed with significance level = 0.05 and multiple testing adjustments were done using 
Benjamini Hochberg FDR adjustments implemented in the software R. Subgroup 
analyses were carried out in the GSE9891 dataset using all subgroups (including the set 
of individuals (n=34) not assigned to a subgroup) for the purposes of pooled variance 
estimation. 
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Chapter 3 
Iron phenotype is altered in tumors of patients with HGOSC and is correlated with 
the outcome of the patients 
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Chapter 3 
3.1 Chapter Introduction 
As discussed in the introduction, iron metabolism is found to be altered in several types 
of cancer. However, it has not been studied extensively in ovarian cancer, particularly 
HGSOC. Our first step was therefore to study the expression pattern for the iron genes 
and proteins (especially TFR and FPN) within the tumor tissues of HGSOC patients. We 
also explored if expression of TFR/FPN correlates with patient survival. 
3.2 Results 
3.2.1 HGSOC is characterized by consistent alterations in expression of iron-
related genes and proteins 
We began by testing whether iron metabolism was altered in HGSOC by assessing levels 
of transferrin receptor 1 (TFRC) and ferroportin (FPN), proteins that play a central role in 
iron metabolism by regulating the uptake and efflux of iron, respectively.  As seen in Fig. 
4, immunohistochemistry of normal ovarian epithelium versus tissue from patients with 
HGSOC revealed that the iron importer TFRC was strongly expressed (p =2x10-7) and 
the iron efflux protein FPN was weakly expressed (p =2x10-11) in HGSOC when compared 
to normal ovarian epithelia.   Because of a growing body of evidence that serous tubal 
intra-epithelial carcinoma (STIC) is a precursor lesion of HGSOC within the fimbrial region 
of the fallopian tubes (87-89), we also compared the staining of normal ovary to STIC.  It 
revealed the same trend:  TFRC was elevated (p =3x10-7) and FPN was decreased (p 
=5x10-6) in STIC relative to the normal ovary.  Since HGSOC is suspected to originate in 
fimbria, we also performed IHC analysis of normal fimbria compared to HGSOC.  Staining 
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of these cells similarly revealed an increase in TFRC (p =0.0001) and decrease in FPN 
(p =7x10-7) when compared to HGSOC.   
IRP2 is a post-transcriptional regulator of TFRC and FPN that is overexpressed in some 
cancers (24). Since overexpression of IRP2 would lead to an increase in TFRC and 
decrease in FPN, we also assessed levels of IRP2 in our samples of normal and 
malignant ovary (Fig. 4).  Although IRP2 was substantially increased in STIC (p =3x10-8) 
and was modestly elevated in HGSOC (p =0.0008) when compared to normal fimbria, it 
was not statistically different in HGSOC versus normal ovary, suggesting that differences 
in levels of IRP2 alone cannot account for all of the observed changes in TFRC and FPN.  
Collectively, these results suggest a phenotype of increased iron retention in ovarian 
cancer cells when compared to epithelial cells of the non-malignant ovary and oviduct 
fimbria. 
We tested whether this profile of iron retention was also characteristic of low grade serous 
ovarian cancer (LGSOC), a less aggressive form of ovarian cancer with a more favorable 
prognosis that is believed to have a different pathogenesis than HGSOC (90, 91).  As 
shown in Fig. 5, IHC staining for TFRC, FPN and IRP2 revealed that malignant tissue 
from patients with LGSOC exhibited a staining profile that was quite distinct from HGSOC 
and more reminiscent of normal tissue, with decreased TFRC (p =0.001), increased FPN 
(p =0.0001)and decreased IRP2 (p =5.9x10-6) relative to HGSOC.  We also performed 
IHC staining for ferritin, an iron storage protein composed of H and L subunits that is 
translationally induced by iron and frequently used as a marker of elevated intracellular 
iron (92). Consistent with a picture of excess iron acquisition and retention in HGSOC, 
staining for either ferritin H or ferritin L demonstrated an increase in HG vs LG ovarian 
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cancer (p =1.6x10-8) (Fig. 6), as well as in HGSOC vs normal ovary or fallopian tube (Fig. 
5).  Thus, a profile of iron retention characterizes HGSOC, an ovarian cancer subtype 
with an especially poor prognosis. 
To determine whether changes in TFRC and FPN were observed at the RNA as well as 
protein level, we examined several publicly available gene expression datasets from 
ovarian cancer patients.  In a study (GSE69428) comparing normal oviduct to HGSOC 
within the same patient, we observed a decrease in FPN mRNA in tumor tissue (p= 
0.0001, paired t test) (Fig. 7).  Results for TFRC were inconsistent, with some probes 
showing an increase and some showing a decrease between normal and tumor.  
Comparison of low grade to high grade ovarian cancer (GSE27651) showed a significant 
decrease in FPN (p = 0.05, two-tailed t-test) and a similar inconsistency in TFRC (Fig. 8).  
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Fig. 4. Proteins that control intracellular iron are altered high grade serous ovarian 
cancer (HGSOC). Representative images of immunohistochemical staining of normal 
fimbria, normal ovary surface epithelia, serous tubal intra-epithelial carcinoma (STIC) and 
HGSOC stained with antibodies against transferrin receptor 1 (TFRC), ferroportin (FPN) 
and iron regulatory protein 2 (IRP2). Dot plots represent quantification of staining of 
tissues collected from 8 patients with HGSOC and 5 with STIC compared to 8 subjects 
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with normal fimbria and 6 individuals with normal ovarian surface epithelium.  Images of 
three to four random fields per slide were quantified. Differences in TRFC (p<0.0001), 
FPN (p<0.0001 and IRP2 (p<0.01) were statistically significant (one way ANOVA). 
*p<0.001, **p<5x10-5, *** p<5x10-6, ****p<5x10-7, one tailed t test for individual 
comparisons.  Scale bar 1 mm; inset scale bar 10 µm. 
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Fig 5. Proteins that control intracellular iron differ in high grade and low grade 
serous ovarian cancer. Representative images of immunohistochemical staining of 
tumor tissues from patients with low grade serous ovarian cancer (LGSOC) and high 
grade serous ovarian cancer (HGSOC). Proteins stained are ferroportin (FPN), transferrin 
receptor (TFRC), Iron Regulatory Protein 2 (IRP2), ferritin heavy chain (FTH) and ferritin 
light chain (FTL). Dot plots show quantification of staining of tissues from 5 patients with 
LGSOC and 8 patients with HGSOC (3 to 4 random fields from each patient tissue slide). 
*p<0.002. Scale bar 1 mm; inset scale bar 10 μm.  
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Fig 6. Increased expression of ferritin heavy (FTH) and ferritin light chain (FTL) in 
HGSOC. Representative images of immunohistochemical staining using antibodies to 
ferritin heavy chain (FTH) and ferritin light chain (FTL) in normal fimbria, normal ovary 
surface epithelia, and high grade serous ovarian cancer (HGSOC). Dot plots represent 
quantification of staining from multiple patients with HGSOC (8 patients) compared to 
normal fimbria (8 subjects) and normal ovarian surface epithelium (6 subjects) (3 to 4 
random fields from each slide). *p<0.1x10-7; **p<1x10-14; ***p<1x10-16. Scale bar 1 mm; 
inset scale bar 10 μm.  
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Fig 7. Ferroportin expression is decreased in HGSOC compared to normal oviduct. 
Log 2-transformed microarray signal intensity values for ferroportin (SLC40A1) in paired 
samples from 10 normal oviduct and 10 high grade serous ovarian cancer (HGSOC) 
samples (GSE69428). P=0.0001, paired t-test.  
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Fig 8. Ferroportin expression is decreased in high grade serous ovarian cancer 
(HGSOC) compared to low grade serous ovarian cancer (LGSOC). Log 2-transformed 
microarray signal intensity values for ferroportin (SLC40A1) in samples from 13 patients 
with LGSOC and 28 patients with HGSOC (GSE27651). P=0.05, unpaired t-test.  
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3.2.2. Expression of FPN and TFRC are associated with ovarian cancer patient 
prognosis   
We next explored whether the changes in FPN and TFRC were associated with survival 
in ovarian cancer patients.  Using a dataset of 285 patients (GSE9891(34)), we examined 
the relationship between gene expression and overall survival using a Cox proportional 
hazards model.  There was a significant association between FPN and patient survival (p 
= 0.049 and 0.013, respectively, for overall and progression free survival).  We also used 
Kaplan Meier analysis to examine the association between FPN expression and survival, 
and observed a significant increase in both overall and progression-free survival in high 
FPN expressors (p = 6.5 x 10-5, log-rank test (Fig. 9 A,B).  Cox PH analysis did not reveal 
a significant association between TFRC and survival.  
We reasoned that heterogeneity in the patient population contained in the GSE9891 
database might have obscured associations between TFRC and patient outcome.  We 
therefore performed two additional analyses of the association between FPN, TFRC and 
patient outcome.  We first assessed the association between FPN and TFRC and 
molecular subtype.  In their study, Tothill et al. (34) identified and validated six molecular 
subtypes of ovarian cancer that had different clinical outcomes (termed C1-C6).  Of these, 
C3, representing predominantly serous ovarian cancers of low malignant potential (LMP), 
and C6, early stage endometriod tumors, had the most favorable outcome.  Ferroportin 
expression differed significantly among subgroups (p < 2x10-16, overall F-test), and was 
increased in the good prognosis C3 subgroup in multiple-testing adjusted pairwise 
comparisons to all other subgroups (Fig. 9C).   Similarly, TFRC expression varied 
significantly among subgroups (p=5.6x10-5, overall F-test) and was reduced in the good 
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prognosis C3 subgroup in multiple-testing adjusted pairwise comparisons to C1, C2, and 
C4 subgroups (and marginally to C5) (Fig. 9D). We also examined the association 
between FPN and TFRC and grade, a known indicator of prognosis.  When patients were 
subdivided according to grade, FPN was significantly different across the grade groups 
(p = 0.029), and showed a decrease in mean expression between the lowest and higher 
grades (Fig. 9E). TFRC was also significantly different across grade groups (p = 0.009, 
overall F-test), and showed increased mean expression level with increasing grade (Fig. 
9F).  Thus decreased expression of FPN and increased expression of TFRC characterize 
ovarian cancer patients with poorer prognosis. 
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Fig. 9.  Low ferroportin and high transferrin receptor expression are associated 
with poor prognosis in patients with HGSOC.  (a,b) Kaplan Meier survival curves for 
FPN expression groups based on optimal risk stratification for GSE9891 dataset (p based 
on the log-rank test). (b,c) Boxplots of log2 gene expression levels for FPN and TFRC 
across molecular subtype groups (data from GSE9891).   Shown are significant 
differences between subgroup C3 and other subgroups: *p < 0.05; **p < 0.005; *** p < 
0.0005.  Individuals who were not assigned a molecular subtype are not shown in this 
Fig. (e,f) Boxplots of log2 gene expression levels for FPN and TFRC across tumor grades. 
 
3.3 Chapter summary 
In this chapter we show that iron trait is altered within the tumor tissues of HGSOC 
patients. TFR, the major iron import protein is increased and FPN, the iron exporter 
protein is decreased in tumor tissues when compared to normal fallopian epithelia or 
normal ovary surface epithelia.  STIC, which is thought to be the precursor lesion of 
HGSIC shows same trend of increased iron import and decreased export when compared 
to normal fallopian tube epithelia. There is only a modest or no increase in IRP2 in tumor 
tissue. Ferritin, which is an iron storage protein and is a surrogate marker for iron retention 
is increased in tumor. This comparative iron profile is also demonstrated between low and 
high grade ovarian malignant tissues. FPN mRNA expression in tumor tissue correlates 
with survival of patients. TFR mRNA expression is lower in favorable prognosis subtypes 
of ovarian cancer patients.  
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Chapter 4 
Iron phenotype is altered in ovarian TICs 
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Chapter 4 
4.1. Chapter introduction 
In chapter 3, we have reported an altered iron phenotype in tumor tissues of HGSOC 
patients. An important clinical problem in the management of ovarian cancer is late stage 
diagnosis:  most patients present with advanced disease that has spread.  Patients who 
have been initially treated with successful response suffer from recurrence and 
chemoresistance of the recurrent tumor. Since the recurrence and drug refractoriness of 
cancer is attributed to the remaining TICs, we sought to determine whether alterations in 
iron metabolism could be detected (and thus ultimately potentially targeted) in the TICs 
resident in the tumor tissue. 
4.2. Results 
4.2.1. Iron metabolism is altered in patient-derived ovarian cancer TICs 
To confirm the early appearance of changes in iron homeostasis in TICs, we used a 
second approach.  We isolated tumor-initiating cells directly from HGSOC patients who 
had not received neo-adjuvant therapy and compared them to normal fallopian stem cells 
from the same patient (70)(Yamamoto et al., in preparation).   Patient-derived tumor 
initiating cell clones showed a compact cell morphology and expressed typical markers 
of high-grade ovarian cancer, such as Ki67 (proliferative marker), Krt7 and E-Cadherin 
(epithelial marker), p53 (indication of stabilized p53 protein due to mutation), PAX8 
(serous cancer marker)(Yamamoto Y., et al., in preparation).  Cells were tumorigenic in 
immunodeficient mice and xenografts derived from these cells exhibited a similar 
expression profile to the primary tumor (Yamamoto Y., et al., in preparation).   
 
 
45 
 
Analysis revealed a profile of iron acquisition and retention in patient-derived TICs with a 
decrease in FPN, an increase in TFRC (Fig. 10A-F), and an increase in ferritin (Fig. 
10G,H). The net effect of increased iron import and decreased iron export should be 
increase in the labile iron pool (LIP). We found that the LIP (Fig. 10I) is increased with 
the TICs relative to normal fallopian tube stem cells.  Cells derived from a second, 
independent, patient donor yielded similar results at mRNA levels (Fig. 11).  Thus ovarian 
cancer TICs exhibit a profile of increased iron retention.   
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Fig.  10.  Iron metabolism is altered in patient-derived normal stem cells and tumor 
initiating cells.  (A) Representative images of immunofluorescent staining of ferroportin 
(FPN) in normal stem cells (CP2-N) and tumor-initiating cells (CP2-OC) derived from the 
same patient.  Green, FPN; blue, nuclei.  (B) Quantification of FPN fluorescence intensity; 
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(C) qRT-PCR of FPN mRNA; (D) Immunofluorescent staining of transferrin receptor 
(TFRC); (E) quantification of TFRC staining intensity: (F) qRT-PCR of TFRC mRNA; (G) 
Immunofluorescent  staining of ferritin H; (H) Quantification of FTH fluorescence intensity; 
(I) Labile iron pool. *p<0.02; **p<0.0002; ***p<2x10-5.  Scale bar 20 µm. 
 
 
 
 
Fig 11. Normal stem cells and tumor initiating cells differ in their iron phenotype. 
Normal and tumor-initiating cells were isolated from a patient with HGSOC (CP34-N and 
CP34-TIC) and expression of ferroportin (FPN) and transferrin receptor 1 measured using 
qRT-PCR with normalization to β-actin.  
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4.2.2. Iron metabolism is altered in a genetic model of ovarian cancer TICs 
HGSOC is characterized by a high level of genomic heterogeneity(51).  Although patient-
derived TICs most closely represent this heterogeneity of the human disease, a model of 
ovarian TIC with limited and defined genetic alterations can help identify specific genetic 
changes that drive alterations in iron metabolism. We therefore built a genetic model of 
TICs in HGSOC by transducing the normal stem cells with SV40TAg, hTERT and c-Myc 
(77), an approach that has been successfully used previously used to model high grade 
serous ovarian cancer (41, 93-95).  Beginning with the normal stem-like cells derived from 
human fimbria, which we term FTstem cells, we first introduced SV40TAg and hTERT by 
retroviral infection to create immortalized but non-tumorigenic FTi cells.  We then we fully 
transformed them by infecting with c-Myc to create FTt cells.  Consistent with the expected 
properties of tumor-initiating cells, as few as two thousand FTt cells were sufficient to form 
palpable tumors in immunodeficient mice in two weeks, and tumor xenografts 
demonstrated major hallmarks of HGSOC, such as loss of PAX2 and gain of p53, EZH2 
and MUC4 expression, and gene expression profiles similar to HGSOC from human 
patients (77).   
We tested whether changes in iron metabolism occurred during the transition of normal 
FTstem cells to malignant FTt cells.  As shown in Fig. 12A-C, there was a progressive 
decrease in FPN expression at both the mRNA and protein levels as cells transitioned 
from normal to immortalized to fully transformed.  Similar to what we observed in the 
tumor tissues of patients with HGSOC, this was accompanied by a progressive increase 
in TFRC (Fig. 12D-F). Since the increase in TFRC would lead to an increase in iron 
uptake, and a decrease in ferroportin would lead to a concomitant decrease in iron efflux, 
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these changes would be anticipated to result in an increase in the metabolically active 
labile iron pool (LIP) as stem cells transition to malignancy.  We tested this prediction by 
measuring the LIP in FTstem, FTi and FTt cells.  As shown in Fig. 12J, the LIP progressively 
increased in these cells.   Consistent with the increase in LIP, which increases the 
translation of ferritin mRNA, there was an increase in ferritin protein without a 
corresponding increase in ferritin H mRNA (Fig. 12G,H, I).  These data suggest that 
perturbations in iron metabolism occur early in the genesis of HGSOC from TICs , and 
that key elements of the changes in iron metabolism can be recapitulated by genetically 
manipulating three defined genes. 
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Fig. 12. Iron metabolism is modified in a genetic model of ovarian cancer tumor 
initiating cells. (A) Immunofluorescent staining of ferroportin (FPN), in normal fallopian 
tube stem cells (FTstem), immortalized fallopian tube stem cells (FTi) and transformed 
fallopian tube stem cells (FTt).  Red, ferroportin; blue, nuclei.  (B) Western blot of 
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ferroportin and β-actin, with Image J quantification of ferroportin/β-actin shown below; (C) 
qRT-PCR of ferroportin mRNA; (D)Immunofluorescent staining of transferrin receptor 1 
(TFRC); (E) TFRC western blot; (F) qRT-PCR of TFRC mRNA; (G) Immunofluorescent 
staining of ferritin heavy chain; (H) Ferritin H western blot; (I) qRT-PCR of ferritin H mRNA; 
(J) labile iron pool.*p<0.02, **p<0.0.0007, ***p<5x10-8; ****p<5x10-11.  Scale bar 20 µm. 
 
4. 3. Chapter summary 
In this chapter we studied the expression of iron proteins in patient derived ovarian TICs. 
Consistent with what we had seen in tumor tissues of HGSOC patients, we see a similar 
iron trait of increased TFR and decreased FPN in ovarian TICs compared to when the 
fallopian stem cells. We also created a genetic model of HGSOC TICs by immortalizing 
fallopian stem cells with hTERT and SV40 and then transforming with c-Myc. In this 
model, we observed that the iron seeking phenotype progressively develops as we go 
from normal to immortalized to fully transformed. This implies that the 3 target genes 
(hTERT, p53, and c-Myc) may have some role (at least in part) in the development of the 
observed iron phenotype in ovarian TICs. As it is expected, the changes in TFR and FPN 
led to increased ferritin and LIP in the ovarian TICs. 
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Chapter 5 
5.1. Chapter introduction 
In previous chapter we see that ovarian TICs exhibit an iron retention phenotype. We 
tested whether the profile of iron acquisition and retention seen in ovarian cancer tumor-
initiating cells is reflective of an enhanced dependence on iron (“iron addiction”)(96).  The 
impetus behind this question is if the TICs possess an iron addiction, it would be a 
potential node to target the TICs through drugs. 
5.2. Results 
Ovarian cancer TICs exhibit enhanced iron dependence 
We treated FTstem, FTi and FTt cells with desferroxamine (DFO), an iron chelator, and 
measured effects on viability.  As shown in Fig. 13A, TICs were remarkably more 
sensitive to iron chelation than normal stem cells; immortalized cells exhibited an 
intermediate sensitivity.   Similarly, patient-derived cancer TICs exhibited an enhanced 
sensitivity to iron depletion when compared to their normal counterparts (Fig. 13B).  To 
confirm the sensitivity of ovarian cancer TICs to iron depletion using a genetic rather than 
pharmacologic approach, we knocked down IRP2 in FTt cells.  As expected, knockdown 
of IRP2 decreased TFRC and increased ferritin, which depletes intracellular iron (Fig. 
13C,D).  Proliferation FTt cells was dramatically inhibited following this genetically-
induced reduction in intracellular iron (Fig. 13E), consistent with the sensitivity of these 
cells to iron depletion by DFO.   
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Fig. 13. Tumor-initiating cells and patient derived cancer stem cells exhibit 
increased iron dependence.  (a, b) Cells were treated for 72 hrs. with the indicated 
concentrations of deferoxamine (DFO) and viability was assessed using an MTS assay. 
(c) Western blot analysis of IRP2, transferrin receptor, (TFRC) and ferritin heavy chain 
(FTH) in IRP2 knock-down in FTt cells (IRP2 KD1, IRP2KD2) and control cells. (d) Colony 
formation in FTt cells treated with control shRNA or IRP2 knockdown vectors. 
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5.3. Chapter summary 
In results shown in this chapter denote that ovarian TICs are sensitive to iron deprivation. 
When iron levels in these cells are decreased (either through treatment of iron chelating 
drugs or by disrupting iron metabolism through IRP2 knockdown), the proliferation is 
inhibited. Interestingly this effect was more prominent in the TICs when compared to 
normal stem cells. This finding opens a new avenue of targeting TICs selectively without 
affecting the normal stem cells.  
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Chapter 6 
6.1. Chapter introduction 
In this chapter we explored if the tumorigenicity of ovarian TICs can be modulated by 
targeting the iron addiction in these cells. To study this, we adopted two different ways: 
by increasing the iron efflux and by inducing an iron dependent cell death (ferroptosis). 
Previously we have observed that iron genes and proteins are altered in ovarian TICs. 
We asked the question if the altered iron metabolism is driver or just passenger in 
malignant dissemination of ovarian cancer.  To study that we chose to manipulate FPN, 
a protein that was consistently reduced in ovarian cancer tissues (Fig. 4) and tumor-
initiating cells (Fig. 10-12), and assessed the effect of increasing its expression in ovarian 
cancer tumor-initiating cells. 
In the second approach we induced an iron-dependent form of cell death, called 
ferroptosis in the TICs. The rationale behind this was to take advantage of the increased 
iron levels in the ovarian TICs and target it to modulate tumor formation. Ferroptosis is a 
mechanism of cell death first identified during a screen for novel cancer therapeutics (97, 
98).  Ferroptosis is a morphologically and mechanistically distinct form of cell death that 
is distinguished by its dependence on iron.  Ferroptosis causes cell death through iron-
mediated accumulation of lipid ROS (97, 99), and can be induced by small molecules 
such as erastin (98), and inhibited by specifically designed molecules such as ferrostatin 
(Fer-1)(97).  Despite its route of discovery, erastin and other ferroptosis-inducers do not 
require oncogenic HRAS for activity (100).  We reasoned that the excess iron retained by 
ovarian cancer tumor-initiating cells might render them more susceptible to agents that 
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induce ferroptosis.  To test this hypothesis, we measured the effect of treating ovarian 
cancer tumor-initiating cells and non-cancer stem cells with erastin.   
6.2. Results 
6.2.1. An increase in iron efflux decreases the malignancy of ovarian cancer tumor-
initiating cells 
We overexpressed FPN in the TICs by a conditional doxycycline-driven promoter (FPN-
tet-on).  Overexpression of FPN reduces intracellular iron by enhancing iron efflux, thus 
enabling us to test the consequences of altered intracellular iron on the proliferation and 
tumor-forming ability of ovarian cancer tumor-initiating cells.  As shown in Fig. 15, 
following induction of FPN with doxycycline, cells exhibited the predicted increase in FPN 
and decrease in intracellular iron.  This was accompanied by a significant reduction in cell 
number (Fig. 14A), indicating that a change in the level of FPN is in itself sufficient to 
modulate tumor-initiating cell proliferation in vitro.   
A defining characteristic of tumor-initiating cells is their high degree of tumorigenicity in 
vivo (101); this was also observed in our FTt cells.  To assess whether high intracellular 
iron contributes to tumor growth in vivo, we injected NSG mice intraperitoneally with FTt 
cells containing doxycycline-inducible FPN or control empty vector.  Mice were treated 
with vehicle or with doxycycline, and tumors were allowed to grow for 4 weeks before 
sacrificing the mice.   IHC analysis confirmed the induction of FPN in tumors of mice 
treated with doxycycline (Fig. 16).  As illustrated in Fig. 14B, necropsy revealed widely 
disseminated tumors in control mice, reminiscent of tumors observed in ovarian cancer 
patients with advanced disease.  FPN-overexpressing cells also gave rise to tumors, but 
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the tumor burden and area of metastasis were markedly reduced relative to controls.   
Mice injected with tumor cells that did not overexpress FPN also exhibited large blood 
vessels supplying small and multiple metastases; these were not evident in mice with 
FPN-overexpressing tumors.  Quantification revealed a significant decrease in tumor 
number (p=0.003) as well as a significant decrease in tumor mass (p=4.6x10-7) in mice 
whose tumors over-expressed FPN (Fig. 14C,D).  
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Fig. 14. Increased iron efflux decreases cell viability and tumorigenicity of ovarian 
cancer tumor-initiating cells. (A) Cell viability of FTt cells as assayed by MTS assay at 
indicated time points with and without ferroportin overexpression.  Blue line represents 
control (empty vector with doxycycline), and red line represents FPN
IND
FTt cells 
(ferroportin tet on with doxycycline).  *p<0.0002, one tail t test. (B) Representative images 
of mice inoculated IP with FPN
IND
 FTt cells and left untreated (left) or treated with 
doxycycline (right) for four weeks to induce expression of ferroportin. Untreated mice have 
a greater tumor burden and wider area of metastasis (circled in white).  (C) Quantification 
of tumor number/mouse and (D) tumor mass/mouse following implantation of tumor cells 
containing empty vector (n=9) or tet-on FPN (n=10) following 4 weeks of doxycycline 
treatment.   
 
 
 
62 
 
 
Fig 15. Ferroportin is induced and the labile iron pool is decreased following 
treatment of conditional ferroportin-overexpressing FTt cells with doxycycline. (A) 
qRT-PCR measurement of ferroportin (FPN) mRNA in cells infected with empty vector or 
a tet-on FPN vector following treatment with doxycycline. (B) immunofluorescent staining 
of ferroportin in cells infected with control or tet-on ferroportin vector following treatment 
with doxycycline. Red, ferroportin; blue, nuclei. (D) Labile iron pool in control or tet-on 
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ferroportin cells. Means and standard deviations of sextuplicate cultures. Scale bar 20 
μm.  
 
 
Fig 16. Tumors isolated from mice injected with FTt tet-on FPN cells over-express 
ferroportin. Ferroportin was quantified by IHC staining of the tumor xenografts.  
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6.2.2. Iron flux through ferroportin affects invasion of ovarian cancer tumor-
initiating cells 
Ovarian cancer is characterized by a propensity towards intraperitoneal tumor spread.  
This is believed to arise from tumor cells that originate in the primary tumor and invade 
locally to colonize the peritoneal cavity.  Because overexpressing FPN markedly reduced 
the number of tumors after intraperitoneal injection, we asked whether iron levels might 
directly affect tumor cell invasion.  We tested the invasion of FTt cells following induction 
of FPN.  Because FPN affects cell proliferation (Fig. 14A), we corrected for cell number 
by comparing the number of cells that migrated through a layer of basement membrane 
protein to those that migrated through an uncoated porous membrane (Fig. 17A).  Viable 
cells expressing FPN showed substantially reduced invasion when compared to controls.  
Consistent with these results, expression of matrix metalloproteases MMP2, MMP9, 
MMP14 and uPA, enzymes that degrade the extracellular matrix, were all reduced in 
cancer tumor-initiating cells following induction of FPN (Fig. 18).  Thus, iron augments 
not only proliferation, but invasion and spread of ovarian cancer tumor-initiating cells.   
To understand the mechanism linking iron to invasion, we examined IL6, since this 
cytokine is elevated in ovarian cancer, promotes invasion, and contributes to poor patient 
outcome (102, 103).  Because IL6 is induced via a STAT-3-mediated pathway, we first 
tested whether induction of FPN affected STAT-3 signaling in ovarian cancer tumor 
initiating cells.  As shown in Fig. 17B, induction of FPN decreased STAT-3 signaling in 
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FTt cells.  This was accompanied by a decrease in both IL-6 mRNA and protein in these 
cells (Fig. 17C,D).  Thus, these data suggest that iron accumulation promotes invasion 
of ovarian cancer tumor-initiating cells at least in part through induction of IL-6. 
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Fig. 17. Ferroportin modulates invasion of FTt cells through STAT3 and IL6.(A) In 
vitro invasion was measured in a simplified Boyden chamber consisting of two chambers 
separated by a 8 micron porous filter coated with or without basement membrane extract 
(BME). Invasion was normalized to migration of the cells in the inserts without the BME 
coating.  *p=0.002; **p=5x10-5.  (B) Western blot analysis of p-STAT3 and total STAT-3 in 
FT
t
 cells transduced with empty vector (EV) or FPN-Tet-following 48 hrs. exposure to 
doxycycline.  Band intensities were quantified using ImageJ.  (C) IL6 mRNA was 
assessed using qRT-PCR; (D) IL6 was measured in culture supernates following 48 hrs.’ 
exposure to doxycycline.  *p≤0.0002.    
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Fig 18. Overexpression of ferroportin reduces expression of invasion markers in 
FTt cells. FTt cells containing the FPN-Tet-on or control vector were induced with 
doxycycline and the indicated mRNAs measured using qRT-PCR. MMP2, matrix 
metalloprotease 2; MMP9, matrix metalloprotease 9; MMP14, matrix metalloprotease 14; 
uPA, urokinase plasminogen activator. Means and standard deviations of triplicate 
determinations. 
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6.2.3. Targeting the iron addiction of ovarian cancer tumor-initiating cells by 
inducing ferroptosis 
We induced ferroptosis in the ovarian TICs by treating them with erastin. To confirm that 
cell death was proceeding via ferroptosis, we also treated with the combination of erastin 
and the ferroptosis inhibitor, Fer-1.  As shown in Fig. 19A, erastin decreased cancer 
tumor-initiating cell viability, and effects of erastin were completely blocked in cells treated 
with the combination of erastin and Fer-1 (Fig. 19B,D).  As predicted, cancer tumor-
initiating cells were significantly more susceptible to erastin treatment than non-cancer 
stem cells (Fig. 19A,C).   
To test whether erastin was similarly effective in vivo, we inoculated NSG mice with FTt 
cells and treated them with either vehicle or 20 mg/kg erastin daily for 18 days.  Mice 
were sacrificed and tumor burden measured by both counting tumor number and 
measuring total tumor mass per mouse.  As seen in Fig. 19E,F, erastin treatment 
produced a marked reduction in both tumor number and mass, indicating that ferroptosis-
inducing agents have the potential to successfully target ovarian tumors. 
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Fig. 19.  Erastin induces ferroptosis in tumor-initiating cells and reduces tumor 
number and mass in vivo. (A) 3000 patient-derived normal stem cells (CP2-N) and 
tumor-initiating cells (CP2-TIC) or (c) FTstem and  FTt cells were treated with indicated 
doses of erastin and cell viability assessed 48 hours later.  (B, D) CP2-TIC cells or FTt 
cells were treated with 2 µM of erastin alone or in combination with 2 μM of ferrostatin-1 
for 48 hrs. and cell viability assessed.   *p<0.00005.  (E, F) Mice were injected 
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intraperitoneally with FTt cells and treated for 18 days with either vehicle or 20 mg/kg 
erastin. The number of tumors/mouse and total tumor mass/mouse were measured in the 
vehicle-treated group (n=5) and in the group treated with erastin (n=6). 
 
6.3. Chapter summary 
In this chapter, we show an important finding that iron proteins (at least FPN) in TICs are 
drivers of tumor progression in HGSOC. Induction of FPN in TICs slows the tumor growth 
in mice. In addition, FPN induction also limits the invasion and metastasis of tumors, a 
phenomenon which is a major clinical obstacle for HGSOC management. We also show 
that inhibition of invasiveness of the TICs upon FPN induction may work through 
downregulation of IL-6 p-STAT3 signaling pathway.  
Ferroptosis can be induced in the HGSOC TICs. On account of increased iron levels 
within the TICs compared to normal stem cells, ferroptosis can be used aa a 
chemotherapeutic tool to eradicate the TICs selectively in patients with HGSOC. 
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Chapter 7 
7.1. Summary 
Ovarian cancer is a highly lethal malignancy that has not seen a major therapeutic 
advance in over 30 years. We demonstrate that ovarian cancer exhibits a targetable 
alteration in iron metabolism.  Ferroportin (FPN), an iron efflux pump, is decreased, and 
transferrin receptor (TFRC), an iron importer, is increased in ovarian cancer 
tissue.  Expression of FPN and TFRC are strongly associated with patient 
survival.  Ovarian cancer tumor initiating cells (TICs) demonstrate a similar profile of iron 
excess and an exquisite dependence on iron for proliferation. Alterations in iron 
metabolism in TICs can be mimicked by manipulating p53 and c-myc.  Iron facilitates 
invasion, synthesis of IL6, and intraperitoneal spread of tumor cells in vivo.  Iron 
dependence in TIC can be targeted in two ways:  by reducing intracellular iron with 
chelators, or by treating with agents that induce iron-dependent cell death (ferroptosis). 
Thus, enhanced levels of iron in ovarian cancer TICs create a metabolic vulnerability that 
can be exploited therapeutically.   
 
7.2. Discussion 
Here we have demonstrated that iron metabolism is perturbed in tumors derived from 
patients with HGSOC. HGSOC tumor tissue exhibits an increase in the iron importer 
TFRC, a decrease in the iron efflux pump FPN (Fig 4). Increased import and decreased 
export of iron leads to increased iron retention within the tumor tissue. This is evidenced 
by an increase in the iron storage protein ferritin relative to non-tumor tissue (Fig. 6 ).  
The transition to an “iron-seeking” phenotype appears to be an early event in the 
development of HGSOC, as evidenced by perturbations in patient-derived tumor initiating 
cells and in genetically transformed fallopian tube stem cells (Figs. 10-12).   
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The key objective of cancer therapy is to selectively target the genetic lesions that initiate 
and maintain tumor growth. Most of the cancers harbor multiple genetic alterations, but 
recent preclinical and clinical data supports that cancer cells exhibit dependence on a 
single oncogenic pathway or a protein for its sustained proliferation and survival. The term 
“oncogene addiction” was coined to connote the dependence of cancer cells on the single 
pathway or protein and that switching off this crucial pathway will have devastating effect 
on the cancer growth (104).  Our results suggest that ovarian tumor initiating cells may 
similarly develop an enhanced dependence on iron, or “iron addiction” that can potentially 
be targeted both by agents that induce iron depletion (Fig. 13) and by agents that depend 
on iron for their activity, such as the ferroptosis inducer erastin (Fig. 19).  This is 
particularly relevant for ovarian cancer because of its high genomic heterogeneity and 
such a “moving target” is difficult to destroy. 
Further, we show that changes in iron metabolism in ovarian cancer are not merely 
incidental events or simple bystanders that accompany the transition to malignancy. They 
make important contributions to the growth and metastasis of ovarian cancer cells that is 
reflected in patient prognosis. Thus, reduction of intratumoral iron through upregulation 
of the iron efflux pump ferroportin reduced tumor burden and spread of ovarian cancer in 
the peritoneal cavity of mice (Fig. 16).  In humans, a “high iron” phenotype, particularly 
low ferroportin, was associated with high tumor grade and poor survival (Fig. 9).  Although 
the association of TFRC mRNA with overall survival was less robust than ferroportin, high 
transferrin receptor was also associated with higher grade and molecular subtypes of 
ovarian cancer with poorer survival (Fig. 9). This perhaps implicates that iron efflux as a 
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more prevalent contributor to outcome than iron import, or a predominantly post-
transcriptional mode of TFRC regulation in HGSOC. 
A phenotype of iron acquisition has now been reported in a number of cancers:  
glioblastoma (105), breast(23, 26), prostate(106), and others (3).   Why do cancer cells 
require excess iron?  Iron is required for proliferation and cell cycle progression, and 
upregulation of these processes in cancer cells underpins at least some of their enhanced 
dependence on iron.  Our results suggest that iron may play an additional, unexplored 
role in the malignant process, fostering tumor cell invasion (Fig. 17).  The establishment 
of tumor cells in a metastatic niche requires the acquisition of invasive properties, 
including the ability to degrade the extracellular matrix through the secretion of matrix 
metalloproteases(107).  Elevated levels of intracellular iron appear critical to this process, 
since increasing iron efflux through upregulation of ferroportin led to a decrease in 
expression of several matrix degrading enzymes, including MMPs and uPA (Fig.18).   
How does iron affect expression of MMPs?  We demonstrate that intracellular iron 
upregulates IL6 (Fig. 17), a key cytokine in the initiation and progression of ovarian cancer 
(103, 108).  Elevated levels of IL6 are found in ovarian cancer tissue, and affect tumor 
cell growth, proliferation, and angiogenesis as well as contributing to tumor invasion by 
upregulation of matrix metalloproteases (109).  Iron-mediated upregulation of IL6 is 
consistent with previous work demonstrating that iron chelators inhibit synthesis of IL6 in 
pancreatic cancer cells (110), and that exogenous iron induces IL6 in hepatocytes (111).  
Although details of the pathway linking iron to IL6 are yet to be elucidated, STAT3 may 
play an important role, since a decrease in STAT3 phosphorylation occurred subsequent 
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to iron depletion by ferroportin induction (Fig. 17), and was similarly decreased by iron 
chelation (110). 
Ferroptosis is a recently discovered iron-dependent mode of cell death (98).  Agents that 
trigger ferroptosis represent a potential new class of anti-cancer agents, and are being 
vigorously explored in both preclinical and clinical studies (112).  Iron is required to 
generate the oxidative stress that characterizes ferroptosis, although the precise role 
played by iron remains speculative (100, 113).  We suggest that the enhanced levels of 
iron required for the growth and invasion of ovarian (and other) cancer cells may represent 
an Achilles heel that can be exploited in cancer therapy.   
Our evidence of the vulnerability of tumor-initiating cells to ferroptosis may provide not 
only a new class of compounds that are effective in ovarian cancer, but also an important 
target at which this therapy can be directed: the tumor-initiating cell.    We observed that 
ovarian cancer tumor-initiating cells exhibited decreased FPN, increased TFRC, and 
decreased LIP relative to non-cancer stem cells (Figs. 9-10).  This was accompanied by 
an enhanced sensitivity to erastin, a ferroptosis-inducing agent (Fig. 19).  Erastin was 
also able to profoundly inhibit tumor growth in vivo (Fig. 19).  Since tumor-initiating cells 
are believed to represent treatment-refractory cells that contribute to ovarian cancer drug 
resistance and recurrence (101), the use of ferroptosis-inducing agents in the treatment 
of ovarian cancer, either alone or in combination with conventional therapies, has the 
potential to address a significant clinical problem.   
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7.3. Some limitations of the study 
Ovarian cancer is a disease with high genomic heterogeneity. Cancer phenotype of this 
disease differs from tumor to tumor, from patient to patient. It is therefore important to 
study a big sample size of patients to achieve a statistically significant conclusion about 
ovarian cancer. Given the time frame of my thesis, technical challenges of isolation of 
stem cells, we based our results derived the TICS isolated from 2 patients with HGSOC. 
Though the iron phenotype observed in the patient derived TICs derived from 2 patients 
strongly correlates the findings obtained from the transformed cells used a genetic model 
for the TICs, the small sample size was a big obstacle to make any statistically significant 
conclusion. Our group is in the process of including more HGSOC patients to isolate the 
TICs and reproduce the results we have obtained so far. 
The survival data on ovarian cancer patients are based on the dataset GSE9891. This 
consists of a cohort of 285 patients with different types of ovarian cancer and not just only 
HGSOC. As discussed in the introduction, the origin and pathogenesis of different types 
of ovarian cancer are distinct leading to diversification of the disease histologically, 
genetically and clinically. Our findings of altered iron metabolism are based on tumor 
tissues from HGSOC and TICs isolated from HGSOC patients. Generation of the survival 
data using a cohort consisting of a pure population of HGSOC patients only, will better 
conform our objective. 
In my thesis, we have used a genetic model of HGSOC TICs by transformation of normal 
fallopian stem cells with hTERT, SV40 and c-myc. The concept of origin of cancer stem 
cell or tumor initiating cell is highly debated. While some believe that TICs originate from 
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an oncogenic transformation of normal stem cells (60, 61), there exists a different school 
of thought where it is argued that a TIC may originate “un-differentiation” of a transformed 
non-stem cell (59) .  
The inivo studies in this research study are based on inoculation of transformed fallopian 
stem cells. A more bonafide model of HGSOC animal model would be using the patient 
derived TICs to inoculate the animals. Though we have confirmed that patient derived 
TICs are tumorigenic, but we argue that given the high degree of genomic heterogeneity 
of HGSOC in patients the study of modulating some of the desired iron genes in 
tumorigenicity can be complex. Though there are disadvantages of using a genetic model 
of ovarian TICs for animal studies rather than genuine patient derived TICs, the 
advantages of using transformed cells are that it enables us to dissect out the effects of 
manipulation of certain genes within these cells with a known genetic background.  
Modulating intratumoral iron by increasing iron efflux through FPN decreases tumor 
growth in our animal model. Based on this finding, we claim that iron chelation can be a 
potential chemotherapeutic technique to treat HGSOC. However, it is an over-simplified 
statement in context of treating cancer in human. Cancer patients suffer from associated 
anemia of chronic disease and systemic iron chelation may deteriorate anemia. However 
our findings certainly shed some light in understanding the role of iron in ovarian TICs. 
We believe that our finding will likely help HGSOC treatment with the discovery of tumor 
selective discovery in future. 
We show that FPN induction inhibits invasiveness of ovarian TICs. FPN induction also 
decreases expression of MMPs. We hypothesize that FPN overexpression may 
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downregulate invasion by inhibiting IL-6 signaling since most of the MMPs are induced 
by IL-6. We therefore studied IL-6 signaling and found downregulation of IL-6 expression 
and phosphorylation of STAT-3. These experiments show an association of FPN 
induction, and downregulation of IL-6 and invasion. We do not know if FPN drives 
reduction of IL-6, and thereby causing a change in the invasion. 
We propose ferroptosis inducers to be an efficient chemotherapeutic agent to treat and 
prevent relapses in patients with HGSOC based on our findings that erastin kill TICs and 
halt tumor growth. However the current study does not include any experiments to show 
that erastin is effective in preventing tumor replace when compared to the standard 
chemotherapy used to treat HGSOC. 
7.4. Future directions 
This thesis leads to a number of intriguing questions worthy of future investigation. The 
immediate question that comes to my mind and I believe worth exploring is discussed 
below:  
Is there any mechanistic role of iron in maintaining or regulating the TICs in HGOSC? 
Altered iron metabolism is an early phenomenon in the tumorigenesis in HGSOC since 
we observe the trait at the stage of TICs. It is indeed an important finding, but it raises a 
further interesting question:  does iron have any role in regulating the ovarian TICs? In 
the following discussion, I have summarized the pathways and genes that are known to 
regulate ovarian TICs and where I think there could be potential role of iron. I am also 
going to discuss some experiments which I believe can be designed to find the role of 
iron in regulating such pathways.  
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Several pathways like Notch, Hedgehog, Wnt and transforming growth factor-β (TGF-β), 
are found to be crucial for the regulation of the self-renewal and maintenance of CSC/TICs 
(114-116). Blocking these pathways have been suggested to be a promising strategy to 
target TICs and thus treating recurrent malignancies.  
Notch3 gene is often found overexpressed and amplified in ovarian cancer (117). 
Moreover, Notch3 pathway is found to reprogram HGSOC tumor cells assume an array 
of embryonic stem cell markers and is related to the recurrence of ovarian cancer and is 
responsible for resistance to carboplatin (118). Epigenetic alterations (DNA methylation 
and miRNAs) in multiple Notch target genes are shown clinically significant and correlates 
with HGSOC patient survival (119). Some recent studies have shown that Notch3 
pathway may have important role in maintaining the TICs in HGSOC (117, 120). Another 
study showed that hypoxia induces maintenance of undifferentiated cell state or stem cell 
state via notch signaling pathway (121, 122).   Hypoxia leads to recruitment of HIF-1α to 
a Notch-responsive promoter and activation of Notch downstream genes and thus blocks 
differentiation of stem cells (121). Iron levels can regulate HIF-1α proteins and 
transcription factors. High iron levels can activate HIF (123). HIF1 is also shown to induce 
iron uptake by increasing TFR expression (124, 125). Clearly there is evidence that 
suggests that hypoxia that maintains stem cell state through notch signaling, can also 
induce higher iron retention within progenitor cells and can explain the iron addiction 
exhibited by the ovarian TICs.  
Hedgehog signaling pathway has been well implicated in cancer stem cells of several 
cancers including ovarian cancer (114, 116). Hedgehog pathway is recently reported to 
regulate growth of ovarian cancer spheroid forming cells, suggesting that this pathway be 
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directly involved in maintenance of ovarian TICs (126). Though not in cancer cells, but a 
recent study reported that iron can decrease mRNA levels of HHIPL-2, an inhibitor of 
hedgehog signaling pathway. Thus iron has the ability to increase hedgehog pathway and 
may regulate ovarian TICs. This hypothesis can be tested a simple experiment of 
manipulating iron within our ovarian TICs and measuring the activation of the pathway 
through GLI reporter assay (increased transcriptional activity of GL1 indicates activation 
of hedgehog pathway). 
EMT (Epithelial-mesenchymal transition) is an important cellular reorganization process 
by which epithelial cells loose cell polarity and adhesion and transit to a mesenchymal 
stem cells phenotype with more migratory and invasive properties  and occurs during 
tumorigenesis (127). There is evidence that TICs can be generated through EMT (128, 
129). TGF-β signaling plays an important role in EMT and is indicated in induction of 
ovarian TICs (130). Some recent studies have demonstrated that iron chelators (DFO and 
thiosemicarbazone) inhibit TGF-β-induced EMT in certain cancer cells (131, 132). These 
findings make it tempting to hypothesize that iron may have a role in the induction or 
maintenance of ovarian TICs through EMT pathway. Assay of EMT marker proteins like 
E-cadherin, vimentin, in the ovarian TICs upon alteration of cellular iron may give us a 
better insight in this context. 
Other pathway that is implicated in regulation of TICs is Wnt pathway which is very rare 
in epithelial ovarian cancer (114). Recently it has been shown that iron augments Wnt 
signaling in cells with aberrant APC (133).  
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Besides these signaling pathways, there are many cancer-associated genes that have 
been reported to play functional roles in development and maintenance of TICs. The most 
important gene is probably the TP53. As discussed in the introduction, loss of function pf 
p53, a tumor suppressor protein is indicated in the pathogenesis of HGSOC (50) . A 
recent TCGA study revealed that TP53 mutation is present almost in all HGSOC (96%) 
(48) . A recent study showed that ovarian TICs can be generated by depletion of p53 
expression (134). This demonstrates that p53 dysfunction can enhance the self-renewal 
ability of ovarian stem-like tumor cells. On the other hand, iron is found to regulate p53 
signaling through direct heme-p53 Interaction and Modulation of p53 Localization, 
Stability, and Function (135). Clearly iron may have a crucial role in generation of ovarian 
TICs through p53 in-stabilization. 
Other genes that have been shown to have important roles in regulation and proliferation 
of ovarian TICs are c-kit, TWIST-1, LIN28, Nanog (reviewed in (136)). miRNAs (miR-
199a, miR-214 ) have also been found to be important regulators of ovarian TICs (136). 
Though all of these regulators have no clear connection with iron, but some of them like 
c-kit and miRNAs seem to be affected by iron in both stem cells and non-stem cells (137, 
138). 
The first step to find the association of iron proteins with the genes and pathways that are 
responsible for regulation of ovarian TICs, would be a microarray analysis of our ovarian 
TICs with either knockdown or overexpression of iron genes like TFR, FPN or ferritin. The 
array information will likely bring up the genes (and the pathways) that are significantly 
affected due to alteration of iron metabolism. Further invitro and invivo experiments would 
be necessary to confirm any results. 
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1) Can targeting iron in ovarian TICs prevent relapse of HGSOC? Or, Can ferroptosis 
inducers like erastin overcome the failure of platinum to prevent recurrence? 
As discussed earlier, ovarian cancer is notorious for recurrence and resistance to 
chemotherapy. It has been found that the more aggressive and refractory cancers contain 
more TICs (139, 140). Though the standard surgery and chemotherapy can effectively 
reduce tumor mass in ovarian cancer, most patients with residual ovarian TICs acquire 
replaces and chemoresistance (141, 142). Several mechanisms have been suggested so 
as to how ovarian TICs acquire resistance to drugs: high expression  like drug efflux 
through ABC transporters by TICs (143), enrichment of TICs activation of anti-apoptotic 
factors by TICs (57),  efficient DNA repair  (144-146). Currently a lot of attention is being 
focused at targeting the ovarian TICs. In thesis we have shown that manipulating iron or 
inducing ferroptosis kills ovarian TICs and inhibit tumor progression and invasion. Based 
on the current knowledge that TICs are responsible for cancer recurrence and 
chemoresistance, we anticipate that iron signature in the TICs have some role in those 
two phenomena. It is therefore interesting to explore the iron phenotype in cisplatin 
resistant ovarian cancer cells. The first step in this approach would be to do a comparative 
microarray analysis between cisplatin sensitive and resistant ovarian cancer cells and to 
look for the iron related genes that may be differentially expressed in the two groups of 
cells. While lot of studies are being conducted in identifying genes responsible for 
chemoresistance in ovarian cancer patients, focus has always been biased to the known 
genes involved the regulation of TICs/CSCs. Provided some iron related genes turn out 
to be associated with cisplatin resistance, further experiments with cell lines upon 
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manipulating those specific genes will need to be conducted to expose the specific 
signaling pathways or downstream events.  
7.5. Closing thoughts  
In my thesis, we show that HGSOC is characterized by an altered iron phenotype (High 
TFT, low FPN). This trait is also present within the ovarian TICs. Ovarian TICs exhibit 
an enhanced dependence on iron. This increased sensitivity of the TICs on iron can be 
exploited and potentially utilized to treat HGSOC progression, invasion and perhaps 
recurrence and chemo-resistance.  The findings raise some intriguing questions that 
may be helpful in better understanding of HGSOC and in developing tools to fight this 
dreadful disease. 
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